The First Non-Invasive Treatment for Batten Disease is on its Way.

Introducing Polaryx®. Because we repurpose existing medication, our treatment is safe for prolonged use. Our medication has been validated in an animal model of Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL), and has a potential to treat other types of NCL, including juvenile and infantile forms.

We are seeking partners to develop Polaryx’s® medication for children in need. Are you interested? Click here to reach out.

Contact Now

Polaryx® Highlights

Safe for
prolonged use

Safe for

Backed by an
experienced team

Potential to expand to
other subtypes of NCL, such
as JNCL and INCL

(taken orally)

Cost-effective drug
repurposing strategy

Why Polaryx?®

There’s an urgent need for novel, therapeutic interventions of Batten disease. That’s where Polaryx® comes in.

Learn More

The Technology

Discover our unique methodology that allows Polaryx® to treat Batten disease - non-invasively.

Learn More

The Strengths

Discover what’s holding back current treatments, and where Polaryx® excels.

Learn More

The Pipeline

Learn about the mechanism of action and drug repurposing strategy behind Polaryx®, and more.

Learn More

Meet the team

With over 100 years of combined experience, we're ready to take the fight to Batten disease.

Learn More

The Science

Learn more about Neuronal Ceroid Lipofuscinsosis (NCL), also known as Batten disease.

Learn More

Latest News

image description

Polaryx® Featured in June 2017 Issue of Biopharma Dealmakers

Renowned pharmaceutical industry publication, Biopharma Dealmakers, has featured Polaryx® Therapeturics in their June 2017 edition. Click "read more" now to view the publication.

image description

Polaryx® interviewed by and featured in GHP magazine

To introduce Polaryx® and its technology, GHP magazine has interviewed the Polaryx® team. Click now to see the June 2017 GHP magazine edition. Polaryx® is featured on pages 26-27.

image description

Polaryx Therapeutics Receives Orphan Drug Designation From the U.S. FDA for PLX-200 for Rare Pediatric Disease

This new drug candidate will be used for the treatment of patients with Late Infantile Neuronal Ceroid Lipofuscinosis.

image description

Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100

Polaryx Therapeutics, Inc. is a biotech company developing patient-friendly oral small molecule therapeutics for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) and other forms of NCL, commonly known as Batten disease. Neuronal Ceroid Lipofuscinoses qualify as rare pediatric diseases under Section 529 of the Food, Drug, and Cosmetic Act.

We are seeking partners to help bring Polaryx's®
medications to children in need. Interested?

Click here to reach out.

Contact Now